CSPC Innovation Pharmaceutical to unfreeze 157m shares next year

CSPC Innovation Pharmaceutical announced the upcoming release of 157,520,510 restricted shares, representing 11.2147% of its total share capital, for public trading on November 17, 2025. This release pertains to shares issued for the acquisition of assets from Enbipu Pharmaceutical Co., and associated fundraising. The company confirmed that the sole shareholder involved, Enbipu Pharmaceutical Co., has strictly fulfilled all previous commitments regarding these restricted shares, with no breaches.

The shares were part of an issuance of 72,926,162 new shares to Enbipu Pharmaceutical Co., which listed on the Shenzhen Stock Exchange ChiNext board on November 15, 2022, with a 36-month lock-up period. Following subsequent capital increases and share transfers, the company's total share capital has reached 1,404,592,944 shares.

Independent financial advisors have reviewed the release and confirmed that the number of shares and the listing date comply with relevant regulations. The underlying asset, CSPC Saint Snow Glucose Co., achieved its performance commitments from 2022 to 2024, with cumulative net profits exceeding the promised targets and no impairment in value, negating the need for performance compensation from Enbipu Pharmaceutical Co.